Table 5.
Therapy in Patients with Venous Thromboembolism According to History of Diabetes*
| Diabetes (n = 476) | No Diabetes (n = 2012) | P Value | |
|---|---|---|---|
| Initial therapy | |||
| Warfarin, n (%) | 306 (64.3) | 1285 (63.9) | .86 |
| Intravenous unfractionated heparin, n (%) | 238 (50.0) | 941 (46.8) | .20 |
| Low-molecular-weight heparin, n (%) | 222 (46.6) | 1040 (51.7) | .05 |
| Inferior vena cava filter, n (%) | 74 (15.6) | 220 (10.9) | .01 |
| Subcutaneous unfractionated heparin, n (%) | 28 (5.9) | 66 (3.3) | .01 |
| Fibrinolysis for venous thromboembolism, n (%) | 12 (2.5) | 28 (1.4) | .10 |
| Other parenteral anticoagulant, n (%) | 11 (2.3) | 31 (1.5) | .26 |
| Discharge therapy | |||
| Warfarin alone, n (%) | 182 (40.8) | 752 (39.0) | .48 |
| Low-molecular-weight heparin alone, n (%) | 33 (7.4) | 173 (9.0) | .28 |
| Low-molecular-weight heparin and warfarin, n (%) | 122 (27.4) | 650 (33.7) | .01 |
| Neither, n (%) | 109 (24.4) | 354 (18.4) | .004 |
*
Patients could have received >1 therapeutic modality.